These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

25 related articles for article (PubMed ID: 15278335)

  • 1. Nucleic Acid-based Electrochemical Sensors Facilitate the Study of DNA Binding by Platinum (II)-based Antineoplastics.
    Wu Y; Arroyo-Currás N
    Angew Chem Int Ed Engl; 2024 Mar; 63(12):e202312402. PubMed ID: 38227790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of a light-responsive platinum curcumin complex, chemical and biological investigations and delivery to tumor cells by means of polymeric nanoparticles.
    Vergaro V; Dell'Anna MM; Shahsavari HR; Baldassarre F; Migoni D; Mastrorilli P; Fanizzi FP; Ciccarella G
    Nanoscale Adv; 2023 Sep; 5(19):5340-5351. PubMed ID: 37767039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.
    Cimino GD; Pan CX; Henderson PT
    Bioanalysis; 2013 Feb; 5(3):369-91. PubMed ID: 23394702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaliplatin-DNA adduct formation in white blood cells of cancer patients.
    Pieck AC; Drescher A; Wiesmann KG; Messerschmidt J; Weber G; Strumberg D; Hilger RA; Scheulen ME; Jaehde U
    Br J Cancer; 2008 Jun; 98(12):1959-65. PubMed ID: 18506148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy.
    Kweekel DM; Gelderblom H; Guchelaar HJ
    Cancer Treat Rev; 2005 Apr; 31(2):90-105. PubMed ID: 15847979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
    Milla P; Airoldi M; Weber G; Drescher A; Jaehde U; Cattel L
    Anticancer Drugs; 2009 Jun; 20(5):396-402. PubMed ID: 19287306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A feasibility study of the use of saliva as an alternative to leukocytes as a source of DNA for the study of Pt-DNA adducts in cancer patients receiving platinum-based chemotherapy.
    Taylor SE; Wood JP; Thomas AL; Jones GD; Reid HJ; Sharp BL
    Anal Bioanal Chem; 2014 Dec; 406(30):8033-6. PubMed ID: 25374124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: application to clinical pharmacokinetic studies with oxaliplatin.
    Morrison JG; White P; McDougall S; Firth JW; Woolfrey SG; Graham MA; Greenslade D
    J Pharm Biomed Anal; 2000 Dec; 24(1):1-10. PubMed ID: 11108533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of oxaliplatin-DNA adduct formation in DNA and differentiation of cancer cell drug sensitivity at microdose concentrations.
    Hah SS; Sumbad RA; de Vere White RW; Turteltaub KW; Henderson PT
    Chem Res Toxicol; 2007 Dec; 20(12):1745-51. PubMed ID: 18001055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro studies on the mechanisms of oxaliplatin resistance.
    Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
    Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultratrace voltammetric determination of DNA-bound platinum in patients after administration of oxaliplatin.
    Weber G; Messerschmidt J; Pieck AC; Junker AM; Wehmeier A; Jaehde U
    Anal Bioanal Chem; 2004 Sep; 380(1):54-8. PubMed ID: 15278335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of oxaliplatin: a critical review.
    Graham MA; Lockwood GF; Greenslade D; Brienza S; Bayssas M; Gamelin E
    Clin Cancer Res; 2000 Apr; 6(4):1205-18. PubMed ID: 10778943
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.